Dr. Finch: For a drug wishing to claim efficacy in all these areas, which include acute uncomplicated UrI, pyelonephritis, and any of the subcategories within the complicated group of infections, a population of about 2,500 patients is likely to be required for prospective comparative studies. If the guidelines vary internationally with different criteria in the United States and Japan, this wilt compound the situation and make the process impossibly expensive. Is it therefore necessary to evaluate every new antibiotic to the same degree? With some analogues of an established class of drug (such as a quinolone) it is difficult to predict efficacy. We have learned today about the under-performance of ~-lactams. Is it possible to define criteria which assess the potential performance of an agent? For example, it may be possible to predict activity on the basis of MIC, bactericidal activity, pH susceptibility and kinetic behaviour including tissue and cell uptake. Further exploration of this approach seems desirable if the expense and effort involved in assessing new agents is to remain realistic. Dr. Norrby: I agree with you. But it would put very high demands on the basic documentation to provide some sort of a verification of the hypothesis. This applies specifically to efficacy, microbiological and clinical efficacy. I do not think that the possibility of extrapolation applies to safety. Therefore, the manufacturer must generate data for a very large number of patients for safety documentation. Note that we are talking about uncomplicated cystitis, a disease which by definition is completely harmless; we cannot of course accept any serious adverse drug reactions, even if they are infrequent. Dr. Finch: I think it would be very useful for these guidelines to assess scientific issues concerning predictors of response. This would identify the limitations of present knowledge and encourage novel approaches to these controversial issues. Dr. Westenfelder: My question goes in the same direction: how useful is the investigation of the efficacy of new drugs in the model of uncomplicated urinary tract infection? This is a disease with a spontaneous cure rate of up to 100% compared with complicated urinary tract infection where in a predictable period of time there is no spontaneous cure. So, if there are 300 patients in one arm or even 600 patients, the study will never show any differences. Now, if you have efficacy of less than 95% in this group of patients then the patients you were evaluating are not patients with uncomplicated urinary tract infection but a mixture. Dr. Norrby: I do not agree with you. I think that the last 15 to 20 years have shown us that by doing well-controlled trials we have advanced considerably in our treatment of uncomplicated cystitis. I do not agree that it is unnecessary to do well-designed clinical trials in uncomplicated cystitis. Dr. Naber: According to a study of Mabeck [Postgrad. Med. J. 48 (1972) 69-75] 80% of women with acute symptomatic UTI obtained sterile urine spontaneously within five months. However, antibiotic therapy achieved a much higher immediate cure rate than placebo treatment. Therefore, antibiotic treatment is justified by the prompt therapeutic success. Dr. Westenfelder: That is not the question, whether to treat or not to treat. There is this high spontaneous cure rate in uncomplicated UTI, but there is no spontaneous cure in complicated UTI. This does not mean that uncomplicated UTI should not be treated, but to evaluate the efficacy of new drugs in a model of uncomplicated UTI seems highly questionable to me. Dr. Ludwig: Your approach is very attractive. May I remind you that without the studies on single-dose therapy, three day therapy could not have been developed. My special concern is: how can we translate the results gained by the sophisticated studies into the language of everyday practice? Is there a method by which we can evaluate a drug more efficiently? Can we not say, if it is effective in complicated urinary tract infections when the basic data -pharmacokinetics, tissue values, urine concentrations -are effective, that it will also be effective in uncomplicated UTI? Do we have to perform all these studies in these unfortunate patients? Dr. Neu: It is very easy to have 500 Escherichia coli urinary tract infections. But I would like to know what is effective in Serratia marcescens, Providencia, Morganella spp., the multiresistant Klebsiella spp.? That is what I am really interested in because most drugs treat urinary-tract infections whether given for three days or seven days. How do we set up a trial to show that a quinolone, a dihydrofolate reductase inhibitor or a ~-tactam is better for the small number of organisms that cause urinary tract infection in nursing homes or a patient population with neurological disease? Dr. Nicolle presented about 15 subcategories of complicated urinary tract infection; what is the best drug for each of them? Dr. Norrby: I agree with you. This is where it becomes really difficult because of several factors. Many case studies in complicated UTI have been done on urological wards where several isolates of the same strain in patients have been treated. This is very difficult to evaluate since, if something is odd with one such isolate in either direction, the error will be multiplied by a factor which may be considerable. The design of such studies is extremely difficult and would require true multicentre trials. Dr. Neu: Japanese studies to some extent address that. Centres that have five to ten patients are spread around the country. The US investigator in Tennessee, or Maryland or Wisconsin has provided 200 of the patients for complicated UTI. Dr. Norrby: I am not criticizing the Japanese trials -this is an international problem -loss of patients to follow-up is worrying. What we have done to reduce this problem is to employ nurses whose only job is to visit the patients in their place of work or in their homes and have them produce the urine sample. In that way we find that 90-95% of patients can be recovered for analysis. I get uncomfortable when I see studies where there is a group General Discussion Session IV of patients who are not accounted for. Otherwise I am not criticizing Japan or any other country for having a quality that is higher or lower than anywhere else. Generally, I think, there is a very positive trend: much has happened during the last five or six years in terms of precision, study design, knowledge and basic statistics. We see an extremely positive evolution here, especially in the UTI field.
Dr. Kumazawa: Japan was mentioned, and I would like to tell you about the situation in Japan. In Japan there is the Ministry of Health and Welfare and they say that if there is information on complicated UTI, that drug can also be used for uncomplicated UTI when it is approved. This is one approach, which I do not think we should deny. I would also like to comment on Dr. Norrby's paper concerning acute uncomplicated cystitis. You mentioned that a very large number of patients is necessary, and I agree. But if very many patients are recruited just to prove that a new drug is useless and unsuitable for marketing, who can be made accountable for carrying out such a large scale trial for those hundreds of patients who are treated with useless drugs just to prove that they are useless? It is an ethical question and we would like guidance on the minimum number of patients who would suffer from exposure to useless drugs.
Dr. Kumamoto:
We were discussing for some time the issue of uncomplicated cystitis and the question of follow-up, and someone mentioned the 30% loss in one week and x% in two weeks and the failure to come back. I would like to add to Dr. Norrby's suggestion of sending nurses to collect the patient's urine. I doubt that this is really practical. We think if there is a recurrence, patients will always come back to their doctor. For those who don't come back, it means that they are symptom-free. We take the statistics only from those who come back.
Dr. Norrby: I will start by commenting on Dr. Kumazawa's point, which is very important, on minimizing the problem of large patient samples that arises when you want to prove equivalence. One way is by having a data and safety monitoring committee which has access to all data during the trial and can stop the trial if significance is achieved at a preset level. I would like to return to the patients who are not accounted for. My view, if I am in the position of reviewing a trial either as an editor or in a regulatory position, is that I distrust the investigator. I think that is a negative approach which must be taken in the interests of the critical scientific analysis of data. I then find it difficult not to have the data from all the patients. In the trial which we have published in "The Journal of Infectious Diseases," which is far from perfect, we employed two part-time nurses, one for each site. That cost some money but the nurses were really the main coordinating force. So I think that many of these problems in the day-to-day running of a clinical trial, especially in this type of patient, should be left to well-trained research nurses. They assure quality in the trials. The Americans have that system and agree that they are the ones who ensure quality rather than the investigators. If you talk about patient compliance, that is difficult, but investigator's compliance is far more difficult.
Dr. Newsom: May I comment on Dr. Kumamoto's statement? The patients who come to an uncomplicated urinary tract infection trial receive better care because of the trial protocol and therefore one might hope that this may motivate them to come back.
Dr. Bailey: I would like to return to the discussion we had before on women treated for cystitis. I think there should be a difference between what happens in clinical practice arid in a clinical study. We know that in clinical practiceas our Japanese colleagues have pointed out -most of these women vote with their feet and do not return to the doctor. And I suspect that in real life that is the way it should be. But in clinical studies where you need to assess the results of treatment, these patients really must be followed up. And when we enter patients into studies, as Dr. Norrby has done, they should be told about the need for follow-up and agree to it as part of their informed consent. We find it very easy to have nurses, as Dr. Norrby has done, who visit the patient's house for follow-up. That is the reason why we are able to follow up 100% of the patients enrolled in our studies in general practice.
Dr. Giamarellou:
During the years that we have been doing clinical trials in women with UTI, we have learnt that follow-up should not be omitted. The women often go to the pharmacy and obtain, for instance, ampiciilin without prescription. They have learnt about single-dose or short-term regimens. Therefore they obtain ampicillin or they change their doctor. I think we must make sure that the patient has been cured when he or she does not appear for follow-up. The second point I should like to raise is that after years of clinical trials it has become clear that patients are not evaluable in trials of surgical infection or surgical prophylaxis without a late follow-up. In the latter case a nurse is paid to visit the patient at home one month after the patient has been discharged from the hospital.
